You can't like your own messages.

jdavisDM

Jim Davis
Boston, MA

Joined Nov 23, 2010

Global Commercial Director of Financial Markets for Datamonitor

jamestdavisjr
Weekly Intelligence from @BioPharmInsight. $MDVN, $CELG, $PLX, $GILD, $GE, $LLY. http://t.co/UN3MMwsR

May. 11 at 10:02 AM

from Twitter
jamestdavisjr
$JNJ $BCRX $MDVN $DNDN #BioPharmInsight Intel of the Week + Free Trial Access: http://t.co/UN3MMwsR

Mar. 9 at 11:06 AM

from Twitter
jamestdavisjr
#ACC12 Preview now available from @BioPharmInsight. Send me a note for a copy. $PFE $BMY $JNJ $LLY $ISIS $SNY $MRK $ANTH $AMRN $REGN $RHHBY

Mar. 5 at 11:48 AM

from Twitter
jamestdavisjr
Weekly free #BioPharmInsight intel. $AZN $AMRN $EXAS $SPPI $ALIOF http://t.co/l8CNO1Eb

Mar. 2 at 2:01 PM

from Twitter
jamestdavisjr
$AMRN stands a chance of attaining five-year NCE exclusivity for AMR101 —attorneys. #BioPharmInsight. Free Trial-> http://t.co/6ikmKI3j

Feb. 29 at 3:13 PM

from Twitter
jamestdavisjr
$NVS Gilenya still deemed safe despite EMA-initiated review of deaths- BioPharmInsight http://t.co/diBH5L13

Feb. 15 at 2:23 PM

from Twitter
jamestdavisjr
$ONXX, in difficult size spot, tries for buys, bankers say. #BioPharmInsight. $KERX $ARRY $NVS http://t.co/mucBOQJg

Jan. 31 at 5:42 PM

from Twitter
jamestdavisjr
$GILD not immune to concern over Truvada’s wider HIV use. #BioPharmInsight http://t.co/UkxbXUQE

Jan. 25 at 6:42 AM

from Twitter
jamestdavisjr
$INHX / $BMY deal prompted by $VRUS sale, industry sources say. $IDIX, $ACHN cited as poss trgts. #BioPharmInsight. ww…http://t.co/RxZSISIC

Jan. 11 at 11:01 PM

from Twitter
jamestdavisjr
$ARQL ArQule/Daiichi's tivantinib raises questions about efficacy potential; patient enrolment slow at some sites. #BioPharmInsight

Jan. 10 at 11:27 PM

from Twitter
jamestdavisjr
$GSK / $IPXL IPX-066 NDA filing in late December, good chance of success. #BioPharmInsight. http://t.co/mucBOQJg

Dec. 19 at 1:48 PM

from Twitter
jamestdavisjr
$AMRN Head-to-head against Mochida's Epadel may be needed to obtain method of use patent in pts with very + triglycerides. #BioPharmInsight

Dec. 7 at 3:52 PM

from Twitter
jamestdavisjr
Gilead’s $GILD ‘big bet’ on Pharmasset $VRUS hinges on future results. #BioPharmInsight http://t.co/kIhdFRzh

Dec. 2 at 8:12 AM

from Twitter
jamestdavisjr
$AZN & $ABT 's PARP inhibitors warrant PIII ovarian cancer development; companies proceeding cautiously. #BioPharmIns…http://t.co/RxZSISIC

Nov. 28 at 5:09 PM

from Twitter
jamestdavisjr
$AUXL Xiaflex degree of benefit in Peyronie's trial may be affected by investigator interpretation on study protocol. #BioPharmInsight

Nov. 22 at 11:30 AM

from Twitter

Follow jdavisDM on StockTwits!

Follow investors and traders that match your style and get a personalized stream of news, charts, and ideas.

7 Followers

Trader Profile

Experience: Professional
Assets Traded: Equities

jdavisDM

Add Twitter Connection

Add Facebook Connection

Add LinkedIn Connection

Follow jdavisDM on StockTwits!

Trader Profile

jdavisDM

Add Twitter Connection

Add Facebook Connection

Add LinkedIn Connection

Follow jdavisDM on StockTwits!

Trader Profile

Sign in to StockTwits X

Sign in

Sign up using:

Sign in to StockTwits X

Sign up X

Join StockTwits

Sign up using:

Sign up
using:

Sign up
using: